Core Viewpoint - Fosen Pharmaceutical (01652) experienced a significant stock price surge, rising over 410% at one point and currently up 350% to HKD 1.53, with a trading volume of HKD 13.89 million [1] Group 1: Product Approval - Fosen Pharmaceutical announced that its research and development product, Metformin and Empagliflozin Tablets (I), has received approval from the National Medical Products Administration of China [1] - The product is indicated for the treatment of adult patients with type 2 diabetes who are currently receiving Empagliflozin and Metformin Hydrochloride, aimed at improving blood glucose control in these patients [1] - The board believes that Metformin and Empagliflozin Tablets (I) is an important addition to the company's product pipeline in the diabetes treatment sector [1] Group 2: Market Impact - The approval of this product is expected to provide more treatment options for a large number of diabetes patients [1]
福森药业一度飙升逾410% “二甲双胍恩格列净片(I)”获批上市